979 related articles for article (PubMed ID: 26365210)
1. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
2. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
3. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
[TBL] [Abstract][Full Text] [Related]
4. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
[TBL] [Abstract][Full Text] [Related]
8. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
Keating GM
Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
[TBL] [Abstract][Full Text] [Related]
9. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.
Holland EJ; Whitley WO; Sall K; Lane SS; Raychaudhuri A; Zhang SY; Shojaei A
Curr Med Res Opin; 2016 Oct; 32(10):1759-1765. PubMed ID: 27388660
[TBL] [Abstract][Full Text] [Related]
10. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
Tong AY; Passi SF; Gupta PK
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
[TBL] [Abstract][Full Text] [Related]
13. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
15. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
Tauber J; Berdy GJ; Wirta DL; Krösser S; Vittitow JL;
Ophthalmology; 2023 May; 130(5):516-524. PubMed ID: 36574848
[TBL] [Abstract][Full Text] [Related]
16. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction.
Tauber J
Cornea; 2020 Apr; 39(4):403-407. PubMed ID: 31895884
[TBL] [Abstract][Full Text] [Related]
17. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
[TBL] [Abstract][Full Text] [Related]
18. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
[TBL] [Abstract][Full Text] [Related]
20. Lifitegrast for the treatment of dry eye disease in adults.
Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]